/
INKT
$11.00-$0.36 (-3.17%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$56.6M
5M shares
52-week range
$8.48 – $18.17
26% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-109.00
MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
www.minktherapeutics.com- Employees
- 15
- IPO / List date
- Oct 15, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds INKT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 10,400 | $116.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-28 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded INKT yet.
